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MaPercutaneous left atrial appendage closure technology for stroke prevention in patients with atrial ﬁbrillation has
signiﬁcantly advanced in the past 2 decades. Several devices are under clinical investigation, and a few have already
received Conformité Européene (CE)-mark approval and are available in many countries. The WATCHMAN device (Boston
Scientiﬁc, Natick, Massachusetts) has the most supportive data and is under evaluation by the U.S. Food and Drug
Administration for warfarin-eligible patients. The Amplatzer Cardiac Plug (St. Jude Medical, Plymouth, Minnesota) has a
large real-world experience over the past 5 years, and a randomized trial comparing Amplatzer Cardiac Plug with the
WATCHMAN device is anticipated in the near future. The Lariat procedure (SentreHEART Inc., Redwood City, California)
has also gained interest lately, but early studies were concerning for high rates of serious pericardial effusion and major
bleeding. The current real-world experience predominantly involves patients who are not long-term anticoagulation
candidates or who are perceived to have high bleeding risks. This pattern of practice is expected to change when the U.S.
Food and Drug Administration approves the WATCHMAN device for warfarin-eligible patients. This paper reviews in
depth the procedural techniques, safety, and outcomes of the current leading devices. (J Am Coll Cardiol Intv
2014;7:1205–20) © 2014 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is estimated to affect1.5% to 2% of the general population, andthe prevalence is projected to increase to
12.1 million by 2030 in the United States (1). Unfortu-
nately, AF is a major cause of stroke, increasing
ischemic stroke risk by 5-fold, and is responsible for
15% of all strokes and 30% of strokes in patients age
>80 years (2,3). Strokes associated with AF are also
more severe, with victims having a 50% greater likeli-
hood of becoming disabled or handicapped and >50%
likelihood of death (4,5). Accordingly, stroke preven-
tion with anticoagulation is among the main pillars
of AF management, and anticoagulation guidelines
have become more stringent. The Canadian Car-
diovascular Society recommends anticoagulation for
CHADS2 (congestive heart failure history, hyperten-
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sex female) $1 (6,7).
Several randomized placebo-controlled trials have
demonstrated that oral anticoagulation (OAC) is highly
effective in preventing thromboembolism with AF,
with landmark meta-analysis showing 64% stroke
reduction and 26% mortality reduction with warfarin
(8,9). However, a signiﬁcant proportion (30% to 50%)
of eligible patients do not receive OAC due to absolute
contraindications or perceived risks of bleeding (10).
Long-term therapy with warfarin or novel oral anti-
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
ACP = Amplatzer Cardiac Plug
CCTA = cardiac computed
tomography angiography
CE = Conformité Européene
FDA = Food and Drug
Administration
ICE = intracardiac
echocardiography
LAA = Left atrial appendage
NOAC = novel oral
anticoagulation
OAC = oral anticoagulation
PET = polyethylene
terephthalate
RAO = right anterior oblique
RR = risk ratio
TEE = transesophageal
echocardiography
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1206bleeding risks of 2.1% to 3.6% per year in
recent clinical trials (11–13). Although intra-
cranial hemorrhage is consistently lower with
NOAC, the overall risk of major bleeding is not
diminished with dabigatran or rivaroxaban
compared with warfarin (12,13). Apixaban
was the only agent that reduced major
bleeding (11).
Other concerns and contraindications with
OAC include patients with renal and liver
dysfunctions (for NOAC), high risk of falls,
noncompliance, and those requiring dual an-
tiplatelet therapy after stenting. For warfarin,
there are additional issues with drug and diet
interaction, the need for monitoring, and a
narrow therapeutic window with time in
therapeutic range of only 50% to 60% (14,15).
Even with the relatively well-tolerated NOAC,
the proportion of patients discontinuing
NOAC during study follow-up was 15% to 25%
(11–13). There is also residual stroke risk of
2% to 5% annually despite optimal anti-coagulation (16). These challenges have led to device-
based therapies for nonvalvular AF.
Transesophageal echocardiography (TEE), autopsy,
and surgical reports conﬁrmed that >90% of non-
rheumatic AF-related left atrial thrombi were isolated
to, or originated from, the left atrial appendage (LAA)
(17). Thus, mechanical approaches to exclude the LAA
from systemic circulation were explored, and early
attempts by surgical removal or ligation of LAA
developed over 60 years ago were limited by the
invasiveness and by signiﬁcant rates of incomplete
exclusion that were associated with increased stroke
risks (18,19). Minimally invasive approaches have
been developed over the past 2 decades and can be
broadly divided into endocardial and epicardial de-
vices (Table 1). This paper reviews contemporary
percutaneous LAA closure, with in-depth discussions
of the procedural techniques and clinical outcomes of
leading devices.
INDICATIONS FOR
PERCUTANEOUS LAA CLOSURE
The current indications for percutaneous LAA closure
vary geographically. Recently, the European Society
of Cardiology implemented a class IIB recommenda-
tion for patients with high stroke risk and contrain-
dications to long-term OAC (7). The majority of
procedures performed in Europe adhere to this
guideline as reported by Tzikas (20). Among w1,000
LAA closures, 74% were for patients with major
bleeding or at high bleeding risk. Other indicationsincluded coronary stenting (23%), drug interaction
(18%), stroke on warfarin (16%), renal or hepatic dis-
ease (13%), labile international normalized ratio
(7%), and risk of falls (7%). In Canada, LAA closure
is generally restricted to patients with CHADS2 $1
and contraindications to long-term OAC, under the
Health Canada special access program. In the United
States, the Lariat procedure may be performed
for patients at high risk for stroke with or without
contraindications to OAC, but WATCHMAN may only
be implanted under the CAP2 (Continued Access
Protocol 2) registry for patients eligible for OAC
(up until early 2014), pending U.S. Food and Drug
Administration (FDA) approval.
DEVICES FOR
PERCUTANEOUS LAA OCCLUSION
PLAATO. The PLAATO (Percutaneous Left Atrial
Appendage Transcatheter Occlusion) device (Appriva
Medical Inc., Sunnyvale, California) was the ﬁrst
percutaneous LAA device manufactured with the ﬁrst
human implant in 2001 (21). It consisted of a self-
expanding nitinol cage (diameter 15 to 32 mm) with
3 anchors on each strut to stabilize the occluder. It
was covered with nonthrombogenic polytetraﬂuoro-
ethylene membrane to exclude blood ﬂow into the
remaining LAA. The PLAATO feasibility study in-
volved 64 patients with AF and contraindications
to OAC; the observed annual stroke risk was much
lower than expected based on CHADS2 score (3.8% vs.
6.6%) with 5-year follow-up (22). Despite this prom-
ising early result, the device was withdrawn from the
market for commercial reasons.
WATCHMAN. The second dedicated LAA device to be
manufactured was WATCHMAN, which was originally
owned by Atritech Inc. (Plymouth, Minnesota) but
acquired by Boston Scientiﬁc (Natick, Massachusetts)
in 2011. The current second-generation WATCHMAN
LAA Closure Technology consists of a self-expanding
nitinol frame covered with permeable (160 mm) poly-
ethylene terephthalate (PET) membrane (Figure 1).
There are 10 activeﬁxation anchors at the nitinol frame
perimeter, designed to engage LAA tissue for device
stability. The PET membrane covers w50% of the
proximal outer nitinol frame, which blocks thrombus
embolization from the LAA and promotes healing and
endothelialization. The device’s spherical contour ac-
commodates most LAA anatomy (case example,
Figure 2). There are 5 sizes available (Table 2), deliv-
ered through dedicated 14-F sheaths with 12-F inner
diameter and 75 cm working length. There are 3 dedi-
cated access sheaths: double-curve, single-curve
TABLE 1 LAA Closure Devices
Device Name Company Design Device Sizes Approval Status
Endocardial Devices
PLAATO Appriva Medical Inc. Single-lobe occluder; nitinol cage; ePTFE membrane; hooks 15, 18, 20, 23, 26, 29, and 32 mm
(14-F sheath)
Removed from
market
WATCHMAN Boston Scientiﬁc Single-lobe occluder; nitinol frame; PET membrane; hooks 21, 24, 27, 30, and 33 mm
(14-F sheath)
CE mark
ACP St. Jude Medical Lobe and disk (polyester mesh in both); nitinol mesh structure;
stabilizing wires
16, 18, 20, 22, 24, 26, 28, and
30 mm (9, 10, and 13-F sheaths)
CE mark
Amulet St. Jude Medical Lobe and disk (polyester mesh in both); nitinol mesh structure;
stabilizing wires
16, 18, 20, 22, 25, 28, 31, and
34 mm (12- and 14-F sheaths)
CE mark
WaveCrest Coherex Medical Single-lobe occluder; nitinol frame; polyurethane foam and ePTFE
membrane; retractable anchors
22, 27, and 32 mm CE mark
Occlutech LAA
Occluder
Occlutech Single-lobe occluder; nitinol wire mesh; stabilizing loops;
nanomaterial covering
15, 18, 21, 24, 27, 30, 33, 36, and
39 mm (12- and 14-F sheaths)
Clinical trial
evaluation
Sideris Transcatheter
Patch
Custom Medical
Devices
Frameless detachable latex balloon covered with polyurethane Clinical trial
evaluation
LAmbre Lifetech Lobe and disk; nitinol; PET membrane; distal barbs anchors 16 to 36 mm (7- to 10-F sheaths) Clinical trial
evaluation
Pfm Pfm Medical Dual disk (distal anchor, variable middle connector, proximal disk);
nitinol frame
(8- and 9-F sheaths) Pre-clinical trial
evaluation
Ultrasept Cardia Lobe and disk; nitinol frame; Ivalon covering; distal anchors 16, 20, 24, 28, and 32 mm
(10-, 11-, and 12-F sheaths)
Clinical trial
evaluation
Epicardial Devices
Lariat SentreHeart Endocardial and epicardial approach: magnetically-assisted snare
over balloon in LAA
14-F epicardial sheath FDA approval
CE mark
AtriClip AtriCure Surgical approach: parallel clip with polyester mesh 35, 40, 45, and 50 mm FDA approval
CE mark
Aegis AEGIS Medical
Innovations
Epicardial subxiphoid approach: electrodes guide navigation to
LAA and tissue capture
Clinical trial
evaluation
Cardioblate
Closure System
Medtronic Epicardial approach: silicone band covered by polyester fabric Pre-clinical trial
evaluation
ACP ¼ Amplatzer Cardiac Plug; CE ¼ Conformité Européene; ePTFE ¼ expanded polytetraﬂuoroethylene; FDA ¼ Food and Drug Administration; LAA ¼ left atrial appendage; PET ¼ polyethylene
terephthalate; PLAATO ¼ Percutaneous Left Atrial Appendage Transcatheter Occlusion.
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1207(Figure 1), and anterior-curve. The standard work-
horse is the double-curve sheath (>90% cases), which
allows easier access into superiorly directed distal
lobes. The fourth-generation device was evaluated
in a European registry, and the ﬁfth generation
(WATCHMAN FLX) is awaiting ﬁrst-in-man evalua-
tion. The WATCHMAN device received the Conformité
Européene (CE) mark in 2005 and is under FDA
evaluation with anticipated approval in early 2015.
AMPLATZER CARDIAC PLUG. Early adopters of
percutaneous LAA closure in Europe attempted non-
dedicated Amplatzer devices after the PLAATO device
was discontinued as there was no other option
(23,24). However, the incidence of embolization was
high (12%), although the efﬁcacy endpoints were si-
milar to dedicated devices for successfully-implanted
devices (24). The dedicated Amplatzer Cardiac Plug
(ACP) (St. Jude Medical, Plymouth, Minnesota) was
speciﬁcally designed to occlude the proximal
segment of the LAA and is the third LAA device to be
manufactured.ACP consists of self-expanding nitinol mesh
forming a lobe and disk, connected by a central
articulating waist (Figure 3). The lobe is implanted
w10 mm inside of the LAA oriﬁce and serves as the
key anchoring mechanism, supported by 6 pairs of
stabilizing wires distally. The disk deployed in the left
atrium is pulled under traction against the LAA oriﬁce
by the waist connecting to the lobe, which helps
to seal the oriﬁce (case example, Figure 4). Both the
lobe and disk have polyester mesh that is sewn in
by hand. There are 8 sizes according to the lobe
dimension, accommodating LAA diameters of 12.6 to
28.5 mm (Figure 3). The second-generation ACP,
Amulet (St. Jude Medical), has a wider lobe, longer
waist, recessed proximal end screw, and more stabi-
lizing wires. These features improve the stability of
Amulet and theoretically may reduce thrombus for-
mation on the atrial side of the device. Amulet
also comes in 8 sizes and accommodates larger LAAs
(up to 32 mm).
ACP has to be manually loaded onto the delivery
cable, but the Amulet comes pre-loaded on the
FIGURE 1 WATCHMAN and 14-F Access Sheaths (Double- and Single-Curve)
There are 3 radio-opaque marker bands (33, 27, and 21 mm) on the distal sheath, which should be aligned to the left atrial appendage (LAA)
“ostium” according to the selected device. PTFE ¼ polyethylene terephthalate.
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1208delivery cable for ease of setup. Currently, the Amulet
is undergoing redesign of the delivery system and
will be relaunched in late-2014. ACP received the CE
mark in December 2008, and Amulet received it in
January 2013.
There were 3 ACP/Amulet delivery sheaths avail-
able; the workhorse is the TorqVue 45  45 (>95%
of cases), which has a 3-dimensional distal tip,
allowing anterior and superior angulation for coaxial
positioning at the landing zone. The TVLA1 and TVLA2
sheaths are no longer being manufactured because
of lack of demand. The access sheath size varies
according to the device size (Figure 3), although some
operators routinely use the largest sheath.
LARIAT. The catheter-based Lariat (SentreHEART
Inc., Redwood City, California) LAA closure is a com-
plex hybrid procedure that requires both an endocar-
dial and epicardial approach. Lariat is FDA-approved
(and CE-marked) for suture and knot tying during
surgical applications, but not speciﬁcally for stroke
prevention with AF. There is a recent surge in interest
and procedural volume in the United States due to the
availability of this device for patients who are not OAC
candidates. Lariat consists of a snare with a pre-tied
suture that is magnetically guided epicardially over
the LAA. There are 3 components: a 15-mm compliant
occlusion balloon catheter (EndoCATH); 0.025- and0.035-inch magnet-tipped guidewires (FindrWIRZ);
and a 12-F Lariat suture delivery device (25).IMPLANTATION TECHNIQUES FOR
WATCHMAN AND ACP
PRE-PROCEDURAL IMAGING. Baseline TEE is im-
portant to exclude pre-existing LAA thrombus and
to assess for suitability for LAA closure, especially
for sizing and device selection. A full 0 to 180
sweep is useful to appreciate the LAA anatomy and
for accurate measurements. For WATCHMAN, the
widest LAA ostium (anatomic oriﬁce measured from
the circumﬂex artery inferiorly to a point superiorly
1 to 2 cm within the pulmonary vein ridge) at 0,
45, 90, and 135 and the available depth of the
LAA (from ostium to apex of LAA) are measured. For
ACP, measurements at both the short axis (30 to 60)
and the long axis (120 to 150) of the landing zone and
oriﬁce are important. The LAA oriﬁce represents the
line from the pulmonary vein ridge to the circumﬂex
artery (echocardiographic oriﬁce) (Figure 5). The
landing zone is measured at 10 mm within the oriﬁce
at an angle that is perpendicular to the neck axis. The
LAA depth is measured from the oriﬁce to the back
wall along the neck axis. For Amulet, the landing zone
isw12 to 15 mm from the oriﬁce due to the wider lobe.
TABLE 2 WATCHMAN Studies and Key Results
Study (Ref. #) Design
CHADS2,
Mean  SD
Procedural
Success, %
Follow-Up
Duration Efﬁcacy Events Important Safety Issues With WM
PROTECT-AF
(29,31)
RCT, N ¼ 707:
2 WM;
1 warfarin
2.2  1.2 90.9 1,065 pt-yrs
(mean 1.8 yrs)
Primary endpoint: stroke, systemic embolism,
CV death: 3.0% WM, 4.9% warfarin per
100 pt-yrs; RR: 0.62. Met noninferiority
criteria.
Serious pericardial effusion 4.8%,
procedural stroke 1.3%, device
embolization 0.6%, major bleeding
3.5% (4.1% warfarin), hemorrhagic
stroke 0.2% (2.5% warfarin).
1,588 pt-yrs
(mean 2.3 yrs)
Primary endpoint: 3.0% WM, 4.3% warfarin
per 100 pt-yrs; RR: 0.71. Met
noninferiority criteria.
2,621 pt-yrs
(45 months)
Primary endpoint: 2.3% WM, 3.8%
warfarin per 100 pt-yrs; RR: 0.6. Met
noninferiority and superiority criteria.
Major bleeding 4.8% (7.4% warfarin),
hemorrhagic stroke 0.6%
(3.7% warfarin).
PREVAIL (32) RCT, N ¼ 407:
2 WM;
1 warfarin
2.6  1.0 95.1 18 months Stroke, systemic embolism, CV, and
unexplained death at 18 months: 0.064
both groups, RR: 1.07. Did not meet
noninferiority criteria (<90 pts at
18-month follow-up). Ischemic stroke
or systemic embolism >7 days met
noninferiority criteria: 0.0253 WM;
0.0201 warfarin.
7-day death, ischemic stroke, systemic
embolism, and procedure complications
met noninferiority criteria (2.2% WM).
Pericardial effusion needing
pericardiocentesis, window, or surgery
1.9%. Procedure stroke 0.4%. Device
embolization 0.8%.
CAP (30) Registry,
N ¼ 460
2.4  1.2 95.0 Median 0.4 yr Procedural stroke 0%, serious pericardial
effusion 2.2%.
ASAP (33) Registry,
N ¼ 150
2.8  1.2 94.7 14 months All-cause stroke and systemic embolism
2.3%/yr. Observed ischemic stroke
rate was 77% lower than expected.
Serious procedure- or device-related
events 8.7%. Pericardial effusion with
tamponade 1.3%, device embolism
1.3%, device thrombus 4.0% (with
0.7% causing stroke).
ASAP¼ ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology; CAP¼ Continued Access Protocol; CHADS2¼ congestive heart failure history, hypertension history, age$75
years, diabetes mellitus history, stroke or transient ischemic attack symptoms previously; CV ¼ cardiovascular; PREVAIL ¼ Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in
Patients With Atrial Fibrillation vs. Long-Term Warfarin Therapy; PROTECT-AF ¼ WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation; pt-yrs ¼ patient-years;
RCT ¼ randomized controlled trial; RR ¼ risk ratio; WM ¼ WATCHMAN.
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1209Of note, the LAA measurements are usually wider at
the long axis view (corresponding to caudal projection
on ﬂuoroscopy) compared to the short axis (corre-
sponding to the right anterior oblique [RAO] cranial).
Pre-procedural cardiac computed tomography
angiography (CCTA) is also useful to examine LAA
anatomy and dimension, given the superior spatial
resolution and 3-dimensionality. Moreover, CCTA is
good for ruling out LAA thrombi, especially when
delayed imaging is acquired (negative predictive
value 100%) (26). Thus, CCTA can become a nonin-
vasive alternative to TEE in experienced CCTA cen-
ters and is increasingly routinely performed prior to
LAA closures (27).
PROCEDURAL IMAGING. It is generally recom-
mended that LAA closures with any current CE mark
devices be performed with TEE guidance for accurate
device positioning and safety, typically accompanied
by general anesthesia. However, there are a few
centers adept with intracardiac echocardiography
(ICE) that prefer procedural ICE instead, obviating
the need for general anesthesia. However, obtaining
adequate LAA images can be challenging, and some
overcome this problem by advancing the ICE probe
into the left atrium through another transseptal
puncture. There are also limited centers that rely onﬂuoroscopy alone (24); however, these are typically
very experienced centers for LAA closure, and this is
not advised for the average operator.
VENOUS ACCESS. Right femoral venous access is
preferred because it allows more direct transseptal
access than the left femoral vein does. Access site
should be well prepared with the scalpel, and subcu-
taneous tissues separated by forceps to ease advance-
ment of large 13- to 14-F sheaths. Manual compression,
“ﬁgure-of-8” suture, or pre-closing with the 6-F
Perclose ProGlide Suture-Mediated Closure System
(Abbott Vascular, Temecula, California) are commonly
used for hemostasis.
TRANSSEPTAL PUNCTURE. Transseptal puncture
should be inferiorly and posteriorly located in the
fossa ovalis for both WATCHMAN and ACP implan-
tation, which is well gauged with the bicaval and
short-axis TEE views, respectively. ICE is also useful
to guide transseptal puncture. Very experienced op-
erators sometimes use anatomic landmarks on ﬂuo-
roscopy alone to guide punctures. Although there is a
small study showing good procedural success with
LAA closure through patent foramen ovale (28), it is
generally advised and preferential to perform a
separate transseptal puncture inferoposteriorly that
FIGURE 2 Example of WATCHMAN Implantation
(A) Transesophageal echocardiography (TEE) image at 116 showing left atrial appendage (LAA) with trabeculations in a fan shape. (B) TEE
at 97 with measurements. (C) Pre-procedure cardiac computed tomography angiography showing complex LAA with protruding proximal
pectinate ridge, widest dimension of 30.3 mm, and usable depth of 29 to 33.2 mm. (D) The 14-F double-curve sheath advanced deep over the
marker pigtail. (E) The 33-mm WATCHMAN deployed. (F) Device released after ensuring PASS (position, anchor, size, seal) criteria were
achieved. (G) TEE widest shoulder measurement of 29.5 mm representing 10.6% compression and no signiﬁcant residual leak. (H) Three-
dimensional TEE showing acceptable slight protrusion of the shoulder of the WATCHMAN into the left atrium, with polyethylene terephthalate
fabric covering the device.
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LAA, which is more anterior and superior. Intrave-
nous heparin is administered before or immediately
following transseptal puncture to maintain an acti-
vated clotting time >250 s. It is also important to
attain adequate mean left atrial pressure (w15 mm Hg)
with ﬂuid bolus for accurate measurements.
FLUOROSCOPIC LAA MEASUREMENTS. Following trans-
septal puncture, a 5-F marker pigtail is advanced
into the LAA and cineangiograms are performed in
multiple projections to ascertain the LAA anatomy
and measurements. Caudal projections are usually
better in visualizing the mid-distal LAA for theWATCHMAN device, whereas RAO cranial projections
are better in visualizing ostium and proximal LAA
for ACP. We typically perform $3 angiographic
views, often aided by CCTA for angle selection. For
the WATCHMAN device, we usually perform RAO (20
to 30) caudal (20 to 30), PA caudal (20 to 30), and
RAO (20 to 30) cranial (10 to 20) projections. For
ACP, we usually perform RAO (30) cranial (10), RAO
(30) cranial (30), and PA caudal (20 to 30)
projections.
ACCESS SHEATH ADVANCEMENT. A long (260-cm)
J-tipped stiff 0.035-inch wire (e.g., Amplatz Super
Stiff J-tip 3-mm curve) should be advanced into the
left upper pulmonary vein as a rail for sheath access.
FIGURE 3 ACP and Amulet Characteristics and Available Sheaths
ACP ¼ Amplatzer Cardiac Plug; Fr ¼ French.
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1211The appropriately-sized access sheath is then safely
advanced to the left upper pulmonary vein ostium.
To allow easier access, the venous access should be
well-dilated, and the sheath gently rotated during
advancement to ensure coaxial approach while
crossing the interatrial septum.
For the WATCHMAN device, the 14-F access sheath
is advanced deep into the LAA using a pigtail (5- to 6-F)
before device introduction. RAO 20 to 30 caudal 20
to 30 angulation typically allows good visualization of
the distal lobes for sheath advancement and device
deployment. The access sheath is safely navigated
over the pigtail into the distal segment of the LAA
(Figure 2), until the corresponding radio-opaque
marker band for the device size (Figure 1) is aligned
with the LAA ostium. Once in position, the pigtail is
removed, and often a moderate degree of catheter
torque is required to maintain sheath position in the
distal lobe.
For ACP, the appropriately-sized sheath/dilator
is usually advanced to the left upper pulmonary vein
oriﬁce, and then the sheath is withdrawn slightly and
turned counterclockwise to fall into the LAA ostium.
A J-tip wire or pigtail may be used to facilitate
engagement to minimize traumatizing the thin left
atrium. Usually an RAO cranial projection is used for
ACP sheath positioning and implantation.
WATCHMAN SIZING AND IMPLANTATION STEPS.
WATCHMAN sizing is based on the maximum LAA
ostium diameter, which should be 17 to 31 mm
to accommodate available devices. Oversizing is rec-
ommended by 9% to 25% based on the widest mea-
surement, which generally corresponds to 2- to 4-mm
oversizing. The prepped delivery system containing
the compressed device is then introduced into the
access sheath. The delivery system is advanced until
both the distal marker bands of the delivery system
and access sheath are aligned. The device is then
unsheathed slowly without forward advancement of
the device, preferably inducing apnea for the patient
to allow stable deployment. When the device is
fully unsheathed, the device position is evaluated on
ﬂuoroscopy and TEE. If it is too distal, the device may
be partially recaptured and the access system with-
drawn slightly, then the unsheathing process is reat-
tempted. If the device is too proximal (or sizing or
position is suboptimal), the device can be fully
recaptured, and a new device and delivery system can
be reattempted through the existing 14-F sheath.
Before device release, the 4 “PASS” criteria should
be met: 1) position (device distal or at LAA ostium,
protrusion of shoulder by <40% to 50% of device
depth is acceptable); 2) anchor (testing stability by
retracting the deployment knob and letting go, toassess return to original position); 3) size (device
shoulder compressed 8% to 20% of original size on
TEE); and 4) seal (assess TEE for any residual ﬂow,
must be<5mmbefore release). When these criteria are
met, the device may be released with counterclock-
wise rotation of the core wire for 3 to 5 turns. Final
angiography and TEE assessment are then performed.
ACP SIZING AND IMPLANTATION STEPS. ACP sizing
depends on the widest landing zone on ﬂuoroscopy or
TEE. A standard recommendation is to upsize the
device by 3 to 5 mm for ACP and 2 to 4 mm for the
Amulet device from the widest measured landing
zone. This degree of oversizing improves stability of
the device and proper anchoring of the lobe. How-
ever, caution should be exercised if the landing zone
is very elliptical to avoid dramatic oversizing (>5 mm)
in the narrowest dimension.
The prepped device is advanced to the tip of the
access sheath, which is positioned at the landing
zone of the LAA. The ﬁrst step of deployment is
unsheathing by withdrawal of the delivery sheath to
deploy the “ball” (Figure 5). If the position is adequate
on TEE and ﬂuoroscopy, the remainder of the lobe is
then deployed. If the angle and position of the lobe at
the landing zone is optimal, then the disk can be
FIGURE 4 ACP/Amulet Implantation
(A) Short- and (B) long-axis baseline TEE views showing measurements of the oriﬁce (red arrows) and the landing zone (yellow arrows) at 10 mm (yellow line) within
the oriﬁce. Transseptal puncture in an inferior position on bicaval TEE view (C) and posterior position on short-axis TEE view (D). (E) Cineangiogram with marker pigtail
in the LAA, and same measurements taken as with TEE. (F) TorqueVue 45  45 sheath is advanced with distal tip aligned with the landing zone. (G) First step of ACP/
Amulet deployment is unsheathing to a “ball” conﬁguration. (H) The remainder of the lobe is unsheathed and the position is checked on cineangiogram and TEE. (I) The
disk is then unsheathed. (J) Device position is conﬁrmed on TEE with color Doppler to assess leak. (K) Device is released and ﬁnal cineangiogram performed. Abbre-
viations as in Figures 2 and 3.
Saw and Lempereur J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 1 1 , 2 0 1 4
Percutaneous Left Atrial Appendage Closure N O V E M B E R 2 0 1 4 : 1 2 0 5 – 2 0
1212deployed. This maneuver requires slight traction of
the delivery cable during further unsheathing of the
disk, to separate the lobe from the disk adequately
and to ensure that the disk is deployed in the left
atrium. The position and angulation of the fully
unsheathed device is conﬁrmed on TEE and ﬂuoros-
copy. If unsatisfactory at any point prior to release,
the disk and lobe can be resheathed into the “ball”
conﬁguration, as long as the 2 platinum markers on
the device do not enter the radio-opaque band on the
sheath. If the device positioning/size is inadequate,
or if the platinum markers enter beyond the radio-
opaque band, then the device has to be entirely
removed, and the sheath replaced.
Prior to device release, 5 signs should be present to
ensure proper deployment (examples in Figure 6):
1) tire-shape of the lobe (ensuring adequate
compression of the lobe and engagement of stabiliz-
ing wires); 2) separation of the lobe from the disk
(ensuring good seal of disk); 3) concavity of the disk
(ensuring good seal by traction of the disk from the
lobe); 4) axis of the lobe (should be perpendicular to
the neck axis at landing zone, to ensure proper con-
tact of lobe walls and stabilizing wires); and 5) lobe is
adequately within the circumﬂex artery on TEE(i.e., lobe should be deep enough such that the width
of the lobe is two-thirds or more within the circum-
ﬂex). If there is uncertainty about device stability, a
gentle “pull” of the disk may be performed, but
vigorous wiggle testing is contraindicated. Alterna-
tively, the device can be observed for several minutes
for stability prior to release. The presence of residual
leak is assessed on TEE. Contrast injections can be
performed through the delivery sheath to assess
optimal positioning after ensuring that the system is
deaired. Once a satisfactory position is achieved, the
device is released with counterclockwise rotation of
the delivery cable.
IMPLANTATION TECHNIQUES FOR LARIAT
A pre-operative CCTA is necessary to exclude large
(>40 mm) appendages and other anatomic variants
(e.g., posteriorly rotated LAA under the pulmonary
artery, pericardial adhesions) that preclude the use of
this device, which may occur in up to 20% of cases.
TEE is performed pre-procedurally to exclude LAA
thrombus and during the procedure to verify the
anatomic position of the EndoCATH balloon at the
LAA ostium.
FIGURE 5 Cardiac CCTA of LAA Demonstrating the 4 Most Common Shapes
Measurements for WATCHMAN are shown in the middle column and ACP in the right column. (A to C) Cauliﬂower-shaped LAA; (D to F)
windsock-shaped LAA with mid-distal trabeculations; (G to I) chicken wing LAA, with distal opaciﬁcation of the LAA due to incomplete contrast-
mixing (not thrombus); (J to L) cactus-shaped LAA with trabeculations extending from all directions from the main body. CCTA ¼ cardiac
computed tomography angiography; other abbreviations as in Figures 2 and 3.
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1213The procedure was well described by Bartus et al.
(25) with 4 key steps: 1) pericardial and transseptal
access; 2) placement of the endocardial magnet-
tipped guidewire in the apex of the LAA with
balloon identiﬁcation of the LAA ostium; 3) connec-
tion of the epicardial and endocardial magnet-tipped
guidewires; and 4) snare capture of the LAA with
closure conﬁrmation and release of the pre-tied su-
ture for LAA ligation.
Pericardial access requires an anterior approach
through the subxiphoid area with a 17-gauge epidural
needle, and ﬂuoroscopic guidance in anteroposterior
and lateral views. Following epicardial access, a
0.035-inch guidewire is advanced and left in the
pericardial space while the transseptal puncture is
performed. The EndoCATH back-loaded with the
magnet-tipped 0.025-inch endocardial guidewire is
advanced to the LAA apex through the transseptal
catheter. The epicardial access is then sequentiallydilated to insert the 14-F guide-cannula, and the
0.035-inch epicardial magnet-tipped guidewire is
then placed through the epicardial sheath and
directed toward the LAA to connect with the endo-
cardial magnet. With the EndoCATH balloon inﬂated
at the LAA ostium, the Lariat suture is then guided to
the LAA along the epicardial magnet, and looped over
the LAA to snare it. The snare is closed after conﬁr-
mation on TEE and left atrial angiogram, and suture
tightening and cutting is then performed. A pigtail
catheter is usually left in the pericardial space for
several hours post-procedure.
CLINICAL TRIALS EVALUATING SAFETY AND
EFFICACY OF LAA OCCLUSION
Several studies have evaluated the efﬁcacy and
safety of these LAA occlusion devices for stroke pre-
vention with AF. The majority are early experience
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1214registries, with only 1 randomized controlled trial
published to date.
WATCHMAN. The WATCHMAN device was studied in
the multicenter PROTECT-AF (WATCHMAN Left
Atrial Appendage System for Embolic Protection in
Patients With Atrial Fibrillation) trial (29), where 707
patients with nonvalvular AF and CHADS2 $1 were
randomized to the WATCHMAN device (n ¼ 463) or to
continued warfarin therapy (n ¼ 244) in a 2:1 ratio.
WATCHMAN was successfully implanted in 90.9% of
cases. Warfarin was continued for 45 days with
WATCHMAN and then switched to clopidogrel for 4.5
months (if there is no leak >5 mm on TEE at 45 days),
with aspirin lifelong after implantation. Warfarin was
discontinued in 86% of patients at 45 days and in 92%
at 6 months.
The composite primary efﬁcacy of stroke, systemic
embolism, and cardiovascular death event rates met
noninferiority criteria at 1,065 and 1,588 patient-
years of follow-up. However, the primary adverse
procedure-related events and major bleeding were
higher with the WATCHMAN device (5.5% vs. 3.6%
annually; risk ratio [RR]: 1.53; 95% conﬁdence in-
terval: 0.95 to 2.70) (Table 2) (30,31).
At 45-month (2,621 patient-years) follow-up (pre-
sented at Heart Rhythm Society 2013), the primary
efﬁcacy endpoint was signiﬁcantly lower with the
WATCHMAN device (2.3 events vs. 3.8 events per
100 patient-years; RR: 0.6), meeting both the nonin-
feriority and superiority criteria. Hemorrhagic stroke
(RR: 0.15), cardiovascular death (RR: 0.4), and all-
cause mortality (hazard ratio: 0.66, p ¼ 0.0379) were
also signiﬁcantly lower with the WATCHMAN device.
Due to early safety concerns in PROTECT-AF, the
FDA mandated a second randomized trial to conﬁrm
the late PROTECT-AF and CAP registry safety results
for approval of the device. Thus, the PREVAIL (Pro-
spective Randomized Evaluation of the WATCHMAN
LAA Closure Device in Patients With Atrial Fibrillation
vs. Long-Term Warfarin Therapy) trial was conduct-
ed, which randomized 407 patients in a 2:1 ratio
to WATCHMAN or warfarin. Inclusion criteria was
CHADS2 $2, or CHADS2 ¼ 1 if 1 or more of the
following was present: female sex $75 years of age;
left ventricular ejection fraction 30% to 34.9%; age
65 to 74 years with diabetes or coronary artery dis-
ease; or age $65 years with documented congestive
heart failure. This study was recently published
(Table 2) (32). Successful implantation improved to
95.1%. The safety endpoint met the pre-speciﬁed
noninferiority criterion.
The ASAP (ASA Plavix Feasibility Study With
WATCHMAN Left Atrial Appendage ClosureTechnology) study (33) evaluated 150 patients with
nonvalvular AF and CHADS2$1 whowere ineligible for
warfarin. Patients were treated with thienopyridine
for 6 months and lifelong aspirin after WATCHMAN
implantation. With a mean follow-up duration of
14 months, all-cause stroke and systemic embolism
was 2.3% per year. The observed ischemic stroke rate
was 77% lower than expected based on the CHADS2
score of 2.8 in the cohort.
The CAP2 registry recently stopped enrolment in
the United States in early 2014. The initial CAP
registry showed lower procedural-related events
compared with the early PROTECT-AF results, with
procedural-related stroke of 0%, and serious peri-
cardial effusion of 2.2% with the WATCHMAN device
(30). With the promising long-term results of
PROTECT-AF and improved safety results of PREVAIL
and CAP, the FDA is anticipated to imminently
approve WATCHMAN.
There was a demonstrable learning curve with
improvement in technical success rate and reduction
in complications with increasing experience. The
implant success rate improved from 91.3% in
PROTECT-AF to 95.0% in the subsequent CAP registry
(p ¼ 0.033) (which included only investigators who
previously implanted WATCHMAN in PROTECT-AF),
in conjunction with signiﬁcant reduction in proce-
dural time (56min vs. 50min, p<0.001), therewas also
signiﬁcant decline in procedure- or device-related
safety event rates when comparing the ﬁrst and sec-
ond halves of PROTECT-AF and CAP, with 10.0%, 5.5%,
and 3.7% of patients, respectively, experiencing
events within 7 days of procedure (p ¼ 0.006) (30).
AMPLATZER CARDIAC PLUG. Since the launch of
the ACP in 2008, over 7,000 devices have been
implanted worldwide. The ACP was evaluated in
several small retrospective registries (Table 3), mostly
involving single-center experiences in Europe, Can-
ada, Asia, and Latin America (24,34–43). In aggregate,
>1,100 patients were included in these registries,
showing good safety proﬁle (serious pericardial effu-
sion w1.7%, device embolization w1.1%, ischemic
stroke w0.4%), and procedural success (w96.4%).
Recently, Tzikas (20) presented a pooled ACP
experience of 20 European and Canadian centers
inclusive of 969 patients at Transcatheter Cardio-
vascular Therapeutics 2013. The mean age was 74.9
years, CHA2DS2-VASc score of 4.4, and HAS-BLED
(hypertension, abnormal liver function, abnormal
renal function, stroke, bleeding, labile international
normalized ratios, elderly [age >65 years], drugs,
alcohol) score of 3.2. About 29% were on OAC prior to
implantation. Implantation success was 97.2%, and in
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121593.2% of cases, the ﬁrst device selected was implan-
ted. With follow-up TEE, the closure rate (<3 mm
residual ﬂow) was 97.6%. The rate of periprocedural
major adverse events (7-day death, ischemic stroke,
systemic embolism, and procedure- or device-related
complications requiring major cardiovascular or
endovascular intervention) was 4.1% (mortality 0.6%,
pericardial tamponade 1.2%, device embolization
0.2%, stroke 0.7%). The observed annual stroke rate
was 2.1%, which was 63% lower than the expected
5.6% stroke rate based on CHA2DS2-VASc score,
similar to other smaller registries (24,39,41).
The U.S. pivotal ACP randomized-controlled trial
commenced enrollment in early 2013, randomizing
AF patients with CHADS2 $2 to ACP versus anti-
coagulation (warfarin or dabigatran) in a 2:1 ratio.
However, due to slow enrollment and imminent FDA
approval of WATCHMAN, this study was discontinued
in December 2013 after enrollment of w80 patients.
The study is being redesigned, and it is anticipated
that the new randomized study will involve a non-
inferiority comparison to the WATCHMAN device.
LARIAT. The ﬁrst published single-center experi-
ence with the Lariat procedure included 89 patients
in Poland (25). The mean age was 62 years, CHADS2
score was 1.9, and CHA2DS2-VASc was 2.8. Technical
success was 96%. There were 2 epicardial-related
complications (right ventricular puncture and superﬁ-
cial epigastric artery laceration) and 1 transseptal com-
plication (hemopericardium). Major post-operative
adverse events included 2 severe pericarditis, 1 late
pericardial effusion, 2 unexplained sudden deaths,
and 2 late strokes. Of the 65 patients undergoing
TEE at 1 year, complete LAA closure was observed
in 98%.
More recently, Price et al. (44) published the
multicenter retrospective U.S. experience of 154 pa-
tients who underwent the Lariat procedure. The
procedural time was 76.6 min and technical success
was 94%, but procedural success (without proce-
dural complication) was only 86%. Major adverse
in-hospital events included: signiﬁcant pericardial
effusion (requiring intervention) 10.4%; bleeding
requiring transfusion 4.5%; and emergent cardiac
surgery 2.0%. At median 112 days follow-up, death,
myocardial infarction or stroke occurred in 2.9%.
TEE follow-up was performed in 63 patients
revealing residual leak in 20%, and presence of
thrombus in 4.8%. In summary, this study showed
that even though technical success was acceptable,
the Lariat procedure resulted in worrisome pericar-
dial effusion and bleeding, thus requiring further
evaluation.COMPLICATIONS WITH PERCUTANEOUS
LAA CLOSURE AND MANAGEMENT
The acute complications with WATCHMAN and ACP
appear comparable. With good technical skills and
procedural planning, the risks of procedural ischemic
stroke is <0.5%, serious pericardial effusion 1% to 2%,
and device embolization 0.5% to 1%. Ischemic strokes
may be related to procedural air embolism (in-
adequate device preparation or poor technique)
or thrombus in LAA or on equipment. Baseline im-
aging to exclude pre-existing thrombus, adequate
procedural anticoagulation, and meticulous and
proﬁcient techniques are important to minimize
thromboembolism. Pericardial effusion causing he-
modynamic compromise requires emergent peri-
cardiocentesis, and possibly pericardial window or
surgical intervention for cardiac perforation. Pericar-
ditis related to Lariat procedures is often managed
with nonsteroidal anti-inﬂammatories or with ste-
roids. Device embolization is typically managed by
percutaneous retrieval if feasible. A large arterial
sheath through the femoral artery that is $2-F larger
than the implanting access sheaths is often required
to retrieve the embolized device, in conjunction with
loop-snare and bioptome. An embolized device trap-
ped in the left ventricle is more challenging to
retrieve but can be successfully performed (Figure 7).
Sometimes, surgical removal is required, especially if
the device is trapped by papillary muscles or
trabeculations.
Longer-term potential issues include thrombus on
device and residual leak; thus, follow-up TEE or
CCTA w3 to 6 months post-procedure is typically
performed (and is sometimes repeated at 1 year).
Formation of thrombus on the atrial side of devices
can occur in 2% to 5% of cases with the 3 devices.
These occurrences are purported to occur predomi-
nantly on nonendothelialized device protrusions,
such as the threaded insert with WATCHMAN and the
proximal end screw with ACP, especially if implants
are too deep. Thus, avoiding deep implantations
creating cul-de-sacs, especially avoiding uncovered
proximal LAA trabeculations, have been advised. New
device designs have also been pursued to address
these concerns; for example, Amulet has a recessed
proximal end screw. Although there is no consensus
on management, such thrombotic complications are
usually managed with anticoagulation (OAC or
low-molecular-weight heparin) for 8 to 12 weeks, with
repeat TEE to assess for thrombus resolution before
cessation of anticoagulation. Reported thromboem-
bolic stroke event rates related to device thrombus
are low: 0.3% to 0.7% (30,33).
TABLE 3 Procedural Success and Complications in ACP Registries
ACP Registries (Ref. #)
Enrollment
Period N
CHADS2 Score,
Mean  SD
Procedural
Success, %
Serious
Pericardial
Effusion, %
Embolization,
%
Ischemic
Stroke, %
Total Safety
Events, %
Initial European registry (34) December 2008–
November 2009
143 NA 96 3.5 1.4 2.1 7
Asia-Paciﬁc experience (35) 2009–2010 20 2.3  1.3 95 0 0 0 1 air embolism,
1 thrombus
Latin America (36) 2009–2012 60 3.2  1.1 100 6.6 1.7 0 8.3
Spanish experience (37) 2009–2011 35 2.4  1.5 97.1 0 0 0 0
Polish experience (38) 2009–2012 21 CHA2DS2-VASc
4.4  1.4
95.2 4.8 0 0 0
Iberia registry (42) 2009–2011 213 NA 92.5 1.4 1.9 0.5 5.6; 1.4 deaths
Bern experience (24) 2008–2012 120 CHA2DS2-VASc
3.4  1.7
97.5 1.6 1.6 0.8 6.7 (2 TIA)
Canadian registry (39) 2009–2011 52 3.0  1.0 98.1 0 1.9 0 1.9
Israel experience (40) 2009–2012 100 3.2  1.2 100 1 0 0 1
Belgian registry (43) 2009–2012 90 CHA2DS2-VASc
4.4  1.8
98.9 3.3 0 0 1.1 deaths
European post-marketing
registry (41)
2009–2011 204 2.6  1.3 96.6 2.4 1.5 0 2.9
CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, age 65 to 74 years, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease,
sex female; NA ¼ not available; TIA ¼ transient ischemic attack; other abbreviations as in Tables 1 and 2.
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1216Residual leaks occur in a fair proportion of
WATCHMAN implantations, with some degree of leak
seen in 32% of cases in PROTECT-AF at 12-month
follow-up (36.8% >3 mm, and 63.2% #3 mm). How-
ever, residual leak was not associated with increased
risk of subsequent thromboembolism (45), although
the event rate was low and these ﬁndings were
considered hypothesis generating. For ACP, leak
>5 mm has not been documented; leak 3 to 5 mm
occurs in 0% to 1% of cases (41), and leak <3 mm
occurs in 0% to 16% of cases (35,37,39). The ACP’s low
incidence of leak is presumably related to the double-
disk design. Residual leak has also been demon-
strated with the Lariat procedure, with variable
reported incidence from 2% to 22% at follow-up
TEE (25,44). In cases of residual leak >5 mm, patients
may be continued on long-term anticoagulation (29);
there are also case reports of performing another LAA
closure with a different device for large residual
leaks (46).
SELECTION AND COMPARISON OF
LEADING LAA DEVICES
LAA device choice often depends on the availability
at the institution and country. Although there is no
randomized comparative study, the technical suc-
cess of the leading devices (WATCHMAN and ACP)
appears quite comparable, 95% to 97%. The Lariat
procedure appears to have lower technical success of
93%, with even lower procedural success of 83%(due to major complications). Most operators would
prefer the endocardial route and relegate epicardial
approach to unsuitable anatomy for endocardial
closure (e.g., large LAA with diameter >31 to 32 mm
but <40 mm, or unusual anatomy such as a short
neck).
Although baseline TEE is commonly done, this
technology is limited by spatial resolution and often
does not provide full deﬁnition of the LAA. Baseline
CCTA is very useful to fully appreciate the LAA
complexity, which helps with device selection and
optimizes ﬂuoroscopic views. LAA can be broadly
divided into 4 different shapes (47): chicken wing,
cactus, windsock, and cauliﬂower (Figure 5). How-
ever, LAA anatomy is highly variable and may have
a combination of these characteristics. We pay par-
ticular attention to the anatomy at intended landing
zones evaluating for sphericity, pectinate ridges,
trabeculations, diverticula, and additional lobes.
Detailed measurements are taken at the oriﬁce, in-
tended landing zone, and available depth (Figure 5).
Using 3-dimensional CT reconstruction, we select
the optimal ﬂuoroscopic angles for the different de-
vices: ACP/Amulet requires optimized views for the
proximal/neck of LAA, whereas WATCHMAN requires
better visualization of the body and distal lobes.
Examples of LAA anatomy ranging from easy to
challenging closures with leading devices are shown
in Figures 6 and 7.
In general, both leading devices can accommodate
over 95% of LAA anatomy. The LAA size is an
FIGURE 6 Easy to Intermediate Challenging Anatomies for LAA Closures
(A) Chickenwing LAAwithmoderately-angled (<90) and gentle curvewith apex of bend>15mm fromoriﬁce, easily closedwith the ACP 28-mm
device (B). (C and D) Windsock LAA easily closed with the Amulet device. (E) Cactus LAA with quite eccentric landing zone being narrow in
the right anterior oblique cranial projection but much wider and showing marked ﬁlamentous trabeculations in the caudal projection (F); this
was moderately challenging for LAA closure with the Amulet device. (H to J) Early bifurcating bilobed LAA at w10 mm from oriﬁce,
moderate difﬁculty closing with the Amulet device with lobe abutting against the carina. Abbreviations as in Figures 2 and 3.
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1217important consideration for selection. According
to the manufacturers, the WATCHMAN device can
accommodate a maximum LAA ostium between
17 mm and 31 mm, whereas ACP can accommodate a
maximum LAA landing zone of 12.6 to 28.5 mm
(Amulet between 12.6 mm and 32 mm). The shape of
the LAA may also inﬂuence device choice.WATCHMAN is a relatively spherical device that re-
quires as much LAA depth as the device diameter
does. This may limit implantation where there is
inadequate depth. There is also a threshold as to the
acceptability of shoulder protrusion into the left
atrium with WATCHMAN (the PET membrane covers
w50% of the proximal part of the device, and thus
FIGURE 7 Examples of Challenging LAA Anatomies for Closure
(A to C) Early proximal (10 mm from oriﬁce) acute sharp (>90) chicken wing bend resulting in unstable ACP position at the intended landing
zone. Device embolized the following day and was successfully retrieved by snare. Deeper placement of the ACP or WATCHMAN may result in
stable position, but would compromise coverage of the ostium. (D) Cardiac computed tomography angiography and (E) ﬂuoroscopy showing
proximal (<10 mm from oriﬁce) protruding pectinate ridge (*) precluding stable ACP positioning (F) with compression of the inferior portion of
the ACP lobe, ultimately closed with a 30-mm WATCHMAN (G). (H to J) Short-necked cauliﬂower LAA is not suitable for WATCHMAN, but
should be amenable to closure with Amulet 34-mm device. (K to L) Fluoroscopy and transesophageal echocardiography images of a large early
bifurcation lobe (w10 mm from oriﬁce) resulting in unstable position of the largest 30-mm ACP device; the WATCHMAN or Amulet may be
feasible here. (M) Challenging large (>44 mm) cauliﬂower LAA with a short neck, precluding the use of WATCHMAN or ACP devices or Lariat
procedure. Abbreviations as in Figures 2 and 3.
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1218the device should not protrude greater than this
amount). The ACP, on the other hand, only requires
a depth of w10 mm (Amulet requires depth of 12 to
15 mm). Other important shape considerations are
the presence of protruding pectinate ridges, location
of additional lobes and trabeculations, and angula-
tion at the landing zones. Challenging anatomies
include proximal (#10 mm from oriﬁce) and severely
sharp-angled (>90 bend) chicken wing conﬁgura-
tion, certain cactus conﬁguration, and limiteddepths. A mental visualization of how each device
would optimally sit in the proximal LAA is helpful
for device selection.CONCLUSIONS
Percutaneous LAA closure is an emerging technology
with several CE-marked devices available in many
countries. The WATCHMAN device has the most
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1219supportive data and is anticipated to be approved
imminently by the FDA. For ACP, there has been a
large real-world experience in the past 5 years, and a
randomized trial comparing ACP with WATCHMAN is
anticipated in the near future. The Lariat procedure
has also gained interest lately, but early studies were
concerning for high rates of serious pericardial effu-
sion and major bleeding. There are many other de-
vices under investigation. The current real-world
experience predominantly involves patients who
are not long-term anticoagulation candidates (or
perceived at high risk of bleeding). This pattern of
practice is expected to change if the FDA approves
the WATCHMAN device for warfarin-eligible patients.Before the pendulum swings completely in favor
of LAA closure over OAC, several remaining issues
should be addressed: longer-term follow-up efﬁ-
cacy data; comparative efﬁcacy of LAA closure to
NOAC; additive effects of OAC and LAA closure;
noninferiority comparisons between different LAA
devices; and updated cost-effective analyses for
LAA closure.
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